Conditions: Type 2 Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 56
Healthy volunteers: no

Brief summary:
This study will assess the safety, tolerability, pharmacokinetics, and glucose lowering activity of MK-8245 in participants with type 2 diabetes. The primary hypothesis of the study is that after 4 weeks of treatment, MK-8245 produces a greater reduction in 24 hour weighted mean glucose (WMG) from baseline than placebo.

Detailed description:

Arms:
arm 1: MK-8245, 50 mg, twice daily for 28 days arm 2: Placebo to MK-8245, 50 mg, twice daily

Interventions: intervention 1: MK-8245 intervention 2: Comparator: placebo
Intervention descriptions: intervention 1: MK-8245 50 mg twice daily for 28 days intervention 2: matching placebo to MK-8245 twice daily for 28 days

Protocol document: